​

Inhibrx Biosciences (INBX) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

INBX Stock Forecast

Inhibrx Biosciences (INBX) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $285.00, with a high of $325.00 and a low of $245.00. This represents a 149.26% increase from the last price of $114.34.

- $70 $140 $210 $280 $350 High: $325 Avg: $285 Low: $245 Last Closed Price: $114.34

INBX Stock Rating

Inhibrx Biosciences stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (60.00%), 2 Hold (40.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 2 3 Strong Sell Sell Hold Buy Strong Buy

INBX Price Target Upside V Benchmarks

TypeNameUpside
StockInhibrx Biosciences149.26%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts112
Avg Price Target$245.00$245.00$285.00
Last Closing Price$114.34$114.34$114.34
Upside/Downside114.27%114.27%149.26%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 26-31--4
Aug, 26-21--3
Jul, 26-21--3
Jun, 26-21--3
May, 26-11--2
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 24, 2026H.C. Wainwright$245.00$103.63136.42%114.27%
May 15, 2026Stifel Nicolaus$325.00$108.13200.56%184.24%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 27, 2026CitigroupMarket PerformMarket Performhold
Aug 24, 2026H.C. WainwrightBuyinitialise
Dec 17, 2025CitigroupMarket PerformMarket Performhold
Nov 19, 2025CitigroupMarket PerformMarket Performhold
Jul 23, 2024JMP SecuritiesOutperformMarket Performinitialise
Aug 23, 2023JMP SecuritiesOutperformOutperformhold

Financial Forecast

EPS Forecast

$-50 $-10 $30 $70 $110 $150 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.15$-3.62$-5.12$116.58$-9.04---
Avg Forecast$-2.16$-3.36$-4.39$-5.87$-6.17$-5.04$-2.43$-3.40
High Forecast$-2.16$-3.36$-4.29$-5.87$-6.17$-5.04$-2.43$-3.40
Low Forecast$-2.16$-3.36$-4.49$-5.87$-6.17$-5.04$-2.43$-3.40
Surprise %-0.46%7.74%16.63%-2086.03%46.52%---

Revenue Forecast

$0 $70M $140M $210M $280M $350M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$7.13M$2.19M$1.80M$200.00K$1.30M---
Avg Forecast$6.10M$2.60M$250.00K$250.00K$2.00M$121.96M$337.85M$346.75M
High Forecast$6.10M$2.60M$250.00K$250.00K$2.00M$121.96M$337.85M$346.75M
Low Forecast$6.10M$2.60M$250.00K$250.00K$2.00M$121.96M$337.85M$346.75M
Surprise %16.80%-15.69%620.00%-20.00%-34.84%---

Net Income Forecast

$-500M $0 $500M $1B $2B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-81.77M$-145.23M$-241.36M$1.69B$-140.06M---
Avg Forecast$-84.59M$-97.33M$-271.15M$-276.42M$-290.79M$-237.54M$-114.53M$-160.24M
High Forecast$-67.67M$-77.87M$-216.92M$-276.42M$-290.79M$-237.54M$-114.53M$-160.24M
Low Forecast$-101.50M$-116.80M$-325.39M$-276.42M$-290.79M$-237.54M$-114.53M$-160.24M
Surprise %-3.33%49.21%-10.99%-710.52%-51.84%---

INBX Forecast FAQ

Is Inhibrx Biosciences stock a buy?

Inhibrx Biosciences stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Inhibrx Biosciences is a favorable investment for most analysts.

What is Inhibrx Biosciences's price target?

Inhibrx Biosciences's price target, set by 5 Wall Street analysts, averages $285 over the next 12 months. The price target range spans from $245 at the low end to $325 at the high end, suggesting a potential 149.26% change from the previous closing price of $114.34.

How does Inhibrx Biosciences stock forecast compare to its benchmarks?

Inhibrx Biosciences's stock forecast shows a 149.26% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Inhibrx Biosciences over the past three months?

  • September 2026: 0% Strong Buy, 75.00% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 0% Strong Buy, 66.67% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 0% Strong Buy, 66.67% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.

What is Inhibrx Biosciences’s EPS forecast?

Inhibrx Biosciences's average annual EPS forecast for its fiscal year ending in December 2026 is $-5.04, marking a -44.25% decrease from the reported $-9.04 in 2025. Estimates for the following years are $-2.43 in 2027, and $-3.4 in 2028.

What is Inhibrx Biosciences’s revenue forecast?

Inhibrx Biosciences's average annual revenue forecast for its fiscal year ending in December 2026 is $121.96M, reflecting a 9281.38% increase from the reported $1.3M in 2025. The forecast for 2027 is $337.85M, and $346.76M for 2028.

What is Inhibrx Biosciences’s net income forecast?

Inhibrx Biosciences's net income forecast for the fiscal year ending in December 2026 stands at $-238M, representing an 69.60% increase from the reported $-140M in 2025. Projections indicate $-115M in 2027, and $-160M in 2028.